drugset / Trial / NCT03521219
A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma
Phase 2
Unknown
30 enrolled
The First Affiliated Hospital of Zhengzhou University
Jiangsu HengRui Medicine Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The propose of this study is to confirm safety and efficacy of Apatinib monotherapy in patients with advanced cholangiocarcinoma.
Timeline
- Start
- 2018-02-07
- Primary completion
- 2018-11
- Completion
- 2019-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |